Analysts Set Crescent Biopharma, Inc. (NASDAQ:CBIO) Price Target at $28.00

Posted by Brenda Bartman on Jun 14th, 2026

Crescent Biopharma, Inc. (NASDAQ:CBIO – Get Free Report) has earned an average rating of “Buy” from the nine ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, five have issued a buy rating and three have issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $28.00.

CBIO has been the subject of several recent research reports. Weiss Ratings raised shares of Crescent Biopharma from a “sell (e)” rating to a “sell (d-)” rating in a research report on Wednesday, May 13th. HC Wainwright dropped their price target on shares of Crescent Biopharma from $25.00 to $22.00 and set a “buy” rating for the company in a research report on Monday, March 2nd. Stifel Nicolaus set a $29.00 price target on shares of Crescent Biopharma in a research report on Thursday, February 26th. Finally, Wall Street Zen raised shares of Crescent Biopharma from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th.

Get Our Latest Stock Analysis on Crescent Biopharma

Crescent Biopharma Stock Performance

Shares of CBIO opened at $17.92 on Friday. The company has a 50-day simple moving average of $19.98 and a 200-day simple moving average of $14.85. The firm has a market capitalization of $493.88 million, a P/E ratio of -1.64 and a beta of 1.16. Crescent Biopharma has a 52 week low of $8.72 and a 52 week high of $27.41.

Crescent Biopharma (NASDAQ:CBIO – Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The biopharmaceutical company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.15. The company had revenue of $1.04 million for the quarter, compared to analyst estimates of $0.36 million. As a group, equities analysts forecast that Crescent Biopharma will post -3.22 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. OMERS ADMINISTRATION Corp bought a new stake in Crescent Biopharma during the fourth quarter worth about $138,000. Bank of America Corp DE bought a new stake in Crescent Biopharma during the second quarter worth about $149,000. HRT Financial LP bought a new stake in Crescent Biopharma during the fourth quarter worth about $155,000. Quadrature Capital Ltd bought a new stake in Crescent Biopharma during the fourth quarter worth about $157,000. Finally, Cannon Global Investment Management LLC bought a new stake in Crescent Biopharma during the first quarter worth about $187,000. Institutional investors and hedge funds own 75.19% of the company’s stock.

Crescent Biopharma Company Profile

(Get Free Report)

Crescent Biopharma, Inc (NASDAQ: CBIO) is a clinical‐stage immuno‐oncology company focused on the discovery, development and commercialization of novel therapies for patients with solid tumors. The company’s research strategy centers on combination approaches that enhance anti‐tumor immune responses by simultaneously targeting multiple pathways implicated in immune evasion and tumor growth.

The company’s lead candidate, CPB-201, is a bifunctional fusion protein designed to block programmed death-ligand 1 (PD-L1) while neutralizing transforming growth factor-beta (TGF-β), with the goal of restoring T-cell activity and reducing tumor fibrosis.